Literature DB >> 19682499

Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Michele Bouloy1, Ramon Flick.   

Abstract

The advent of reverse genetics technology has revolutionized the study of RNA viruses, making it possible to manipulate their genomes and evaluate the effects of these changes on their biology and pathogenesis. The fundamental insights gleaned from reverse genetics-based studies over the last several years provide a new momentum for the development of designed therapies for the control and prevention of these viral pathogens. This review summarizes the successes and stumbling blocks in the development of reverse genetics technologies for Rift Valley fever virus and their application to the further dissection of its pathogenesis and the design of new therapeutics and safe and effective vaccines.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19682499      PMCID： PMC2801414          DOI： 10.1016/j.antiviral.2009.08.002

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  199 in total

1.  The cytoplasmic tails of Uukuniemi Virus (Bunyaviridae) G(N) and G(C) glycoproteins are important for intracellular targeting and the budding of virus-like particles.

Authors:  Anna K Overby; Vsevolod L Popov; Ralf F Pettersson; Etienne P A Neve
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody.

Authors:  Ussama M Abdel-Motal; Kim Wigglesworth; Uri Galili
Journal:  Vaccine       Date:  2009-03-28       Impact factor: 3.641

3.  An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus.

Authors:  M T Heise; A Whitmore; J Thompson; M Parsons; A A Grobbelaar; A Kemp; J T Paweska; K Madric; L J White; R Swanepoel; F J Burt
Journal:  Epidemiol Infect       Date:  2009-01-27       Impact factor: 2.451

4.  The S segment of Punta Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in the Syrian hamster and codes for a type I interferon antagonist.

Authors:  Lucy A Perrone; Krishna Narayanan; Melissa Worthy; C J Peters
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

5.  The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.

Authors:  R B Mandell; R Flick; W R Staplin; L D Kaniewski; A K Carzoli; R P Manuszak; J Wang; G R Rossi; N N Vahanian; C J Link
Journal:  Zoonoses Public Health       Date:  2009-08       Impact factor: 2.702

6.  Limitations of green fluorescent protein as a cell lineage marker.

Authors:  E Scott Swenson; Joanna G Price; Timothy Brazelton; Diane S Krause
Journal:  Stem Cells       Date:  2007-07-05       Impact factor: 6.277

7.  In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.

Authors:  Brian B Gowen; Min-Hui Wong; Kie-Hoon Jung; Andrew B Sanders; Michelle Mendenhall; Kevin W Bailey; Yousuke Furuta; Robert W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

8.  Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins.

Authors:  Sonja R Gerrard; Stuart T Nichol
Journal:  Virology       Date:  2006-09-08       Impact factor: 3.616

Review 9.  T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.

Authors:  Yousuke Furuta; Kazumi Takahashi; Kimiyasu Shiraki; Kenichi Sakamoto; Donald F Smee; Dale L Barnard; Brian B Gowen; Justin G Julander; John D Morrey
Journal:  Antiviral Res       Date:  2009-03-06       Impact factor: 5.970

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616
View more
  31 in total

1.  The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.

Authors:  José-Carlos Fernandez; Agnès Billecocq; Jean Paul Durand; Catherine Cêtre-Sossah; Eric Cardinale; Philippe Marianneau; Michel Pépin; Noël Tordo; Michèle Bouloy
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the pools of Dcp2-accessible targets for cap-snatching.

Authors:  Kaycie C Hopkins; Laura M McLane; Tariq Maqbool; Debasis Panda; Beth Gordesky-Gold; Sara Cherry
Journal:  Genes Dev       Date:  2013-07-01       Impact factor: 11.361

4.  Characterization of wild-type and alternate transcription termination signals in the Rift Valley fever virus genome.

Authors:  Estelle Lara; Agnès Billecocq; Psylvia Leger; Michèle Bouloy
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

5.  Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Authors:  Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

Review 6.  Advances in Rift Valley fever research: insights for disease prevention.

Authors:  A Desiree LaBeaud; James W Kazura; Charles H King
Journal:  Curr Opin Infect Dis       Date:  2010-10       Impact factor: 4.915

7.  Curcumin inhibits Rift Valley fever virus replication in human cells.

Authors:  Aarthi Narayanan; Kylene Kehn-Hall; Svetlana Senina; Lindsay Lundberg; Rachel Van Duyne; Irene Guendel; Ravi Das; Alan Baer; Laura Bethel; Michael Turell; Amy Lynn Hartman; Bhaskar Das; Charles Bailey; Fatah Kashanchi
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

8.  Molecular biology of rift valley Fever virus.

Authors:  Michele Bouloy; Friedemann Weber
Journal:  Open Virol J       Date:  2010-04-22

9.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

Review 10.  Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Authors:  Darryl Falzarano; Heinz Feldmann
Journal:  Curr Opin Virol       Date:  2013-06-15       Impact factor: 7.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.